Systemic sclerosis is a rare and complex autoimmune disease
characterized by widespread blood vessel damage, abnormal immune system
activation, and excessive connective tissue fibrosis. These dysfunctions lead
to severe complications affecting multiple organs, including the skin, lungs,
heart, and kidneys.
Angiogenesis, a key process that facilitates the formation of new blood
vessels from existing ones, plays a central role in this pathology. This
mechanism is often impaired in systemic sclerosis, resulting in inefficient
vascularization and exacerbating tissue damage.
Vascular endothelial growth factor (VEGF), a crucial cytokine regulating
angiogenesis, has attracted significant attention as a potential biomarker.
Abnormally high VEGF levels in systemic sclerosis suggest its involvement in
disease progression, making it a promising target for future diagnostic and
therapeutic approaches.
VEGF: a key marker in systemic sclerosis?
This study investigates circulating VEGF levels in patients with
systemic sclerosis and their association with clinical manifestations. Key
findings include:
- Patients with
systemic sclerosis exhibit significantly higher VEGF concentrations
compared to healthy individuals.
- A correlation
was observed between VEGF levels and the severity of clinical
manifestations, particularly digital ulcers, capillary abnormalities, and
skin fibrosis.
- Although VEGF
generally promotes angiogenesis, in this specific context, it appears to
contribute to inefficient and disorganized vascularization, exacerbating
existing vascular abnormalities.
When VEGF becomes a compass for systemic sclerosis
The results suggest that VEGF could serve as a
useful biomarker not only
for assessing the activity of systemic sclerosis but also for predicting its
clinical progression. Its central role in the disease's pathophysiology also
makes it an
especially promising target for developing new therapeutic
strategies. These approaches would aim to restore functional vascularization
while correcting existing abnormalities.
These discoveries pave the way for innovative targeted treatments that
could address vascular abnormalities and slow the progression of this
debilitating disease, thereby improving patients' quality of life.
